Treatment of Inflammatory Bowel Disease in Children
As no curative therapy exists, supportive measures play an important role in the management of patients with inflammatory bowel disease (IBO). Aminosalicylic acid (ASA) compounds and corticosteroids remain the mainstay of medical therapy. Aminosalicylates are recommended for therapy of mild to moder...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1990-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1990/909858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | As no curative therapy exists, supportive measures play an important
role in the management of patients with inflammatory bowel disease
(IBO). Aminosalicylic acid (ASA) compounds and corticosteroids remain the
mainstay of medical therapy. Aminosalicylates are recommended for therapy of
mild to moderate active ulcerative colitis and for the maintenance of remission
in ulcerative colitis. The role of 5-ASA preparations in Crohn's disease is less
clear. In granulomatous colitis, 5-ASA therapy is recommended. With the
development of new delivery systems, the role for 5-ASA in the treatment of
small bowel Crohn's disease is under investigation. Prednisone remains the drug
of choice in severe ulcerative colitis and active Crohn's disease. The role of
immunosuppressive drugs in pediatric patients is unclear. Nutritional therapy has
been an important advance in the treatment of children with Crohn's disease,
especially those with growth failure. Nutritional therapy can consist of combined
total parenteral and enteral nutrition or enteral nutrition alone. An initial period
of total parenteral nutrition followed by a six to eight week course of enteral
therapy with a semisynthetic diet has been shown to be effective in the management
of patients with severe active disease and growth failure. |
|---|---|
| ISSN: | 0835-7900 |